A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for duchenne muscular dystrophy

Clinical Therapeutics

Volumn 36, Issue 5, 2014, Pages 624-637

  Peay, Holly L ^a   Hollin, Ilene ^b   Fischer, Ryan ^a   Bridges, John F P ^b  

^a Parent Project Muscular Dystrophy   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

benefit risk assessment; caregiver; choice behavior; Duchenne muscular dystrophy; patient preferences

Indexed keywords

ADULT; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CAREGIVER; CAUCASIAN; DECISION MAKING; DRUG INDUSTRY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; HEALTH CARE POLICY; HEART ARRHYTHMIA; HUMAN; KNOWLEDGE; LEADERSHIP; LIFESPAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MUSCLE FUNCTION; MUSCLE WEAKNESS; NAUSEA; OUTCOMES RESEARCH; PATIENT ADVOCACY; PHYSICAL DISABILITY; RISK BENEFIT ANALYSIS; SUDDEN DEATH; VOMITING; ECONOMICS; FOOD AND DRUG ADMINISTRATION; INFORMATION PROCESSING; MUSCULAR DYSTROPHY, DUCHENNE; PATIENT PREFERENCE; RISK ASSESSMENT; STATISTICAL MODEL; UNITED STATES;

CAREGIVERS; DATA COLLECTION; HUMANS; MODELS, STATISTICAL; MUSCULAR DYSTROPHY, DUCHENNE; PATIENT ADVOCACY; PATIENT PREFERENCE; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84901346395     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.04.011     Document Type: Article

References (57)

1. Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morb Wkly Rep. 2009;58:1119-1122
2. A.E. Emery Population frequencies of inherited neuromuscular diseases - a world survey Neuromuscul Disord 1 1991 19 29
3. K. Bushby, R. Finkel, and D.J. Birnkrant et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management Lancet Neurol 9 2010 77 93
4. Eagle M, Baudouin SV, Chandler C, et al. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12:926-929.
5. R.F. Pangalila, G.A. van den Bos, and H.J. Stam et al. Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy Disabil Rehabil 34 2012 988 996
6. A. Kenneson, and J.K. Bobo The effect of caregiving on women in families with Duchenne/Becker muscular dystrophy Health Soc Care Community 18 2010 520 528
7. J. Larkindale, W. Yang, and P.F. Hogan et al. Cost of illness for neuromuscular diseases in the US Muscle Nerve 49 2014 431 438
8. L. Ouyang, S.D. Grosse, M.H. Fox, and J. Bolen A national profile of health care and family impacts of children with muscular dystrophy and special health care needs in the United States J Child Neurol 27 2012 569 576
9. L. Ouyang, S.D. Grosse, and A. Kenneson Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population J Child Neurol 23 2008 883 888
10. W.D. Biggar, V.A. Harris, L. Eliasoph, and B. Alman Long-term benefits of Deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade Neuromuscul Disord 16 2006 249 255
11. C. Angelini The role of corticosteroids in muscular dystrophy: a critical appraisal Muscle Nerve 36 2007 424 435
12. K. Bushby, F. Muntoni, and A. Urtizberea et al. Report on the 124th eNMC International workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids Neuro Muscul Disord 14 2004 526 534
13. A. Govoni, F. Magri, and S. Brajkovic et al. Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy Cell Mol Life Sci 70 2013 4585 4602
14. C.P. Milne Prospects for rapid advances in the development of new medicines for special medical needs Clin Pharmacol Ther 95 2014 98 109
15. M. Michaels, and D. Collyar Research advocacy in traditional research settings: questions of influence and legitimacy J.L. Earp, E.A. French, M.B. Gilkey, Patient Advocacy for Healthcare Quality: Strategies for Achieving Patient-Centered Care 2007 Jones and Bartlett Boston, Mass 445 473
16. Parent Project Muscular Dystrophy. Benefit-risk assessments in rare disorders: The case for therapeutic development in Duchenne muscular dystrophy as the prototype for new approaches. http://www.parentprojectmd.org/BR. Accessed April 28, 2014
17. Genetic Alliance UK. New medicines for serious conditions: weighing the risks and benefits. The verdict of a jury of patients. http://www. geneticalliance.org.uk/docs/citizens-jury-report.pdf. Accessed March 1, 2014.
18. Parent Project Muscular Dystrophy: Share Your Brave Story. http://community.parentprojectmd.org/profiles/blog/list?tag=My+BRAVE+Story. Accessed March 1, 2014.
19. D.E. McNeil, C. Davis, and D. Jillapalli et al. Duchenne muscular dystrophy: drug development and regulatory considerations Muscle Nerve 41 2010 740 745
20. B. Hauber, A.O. Fairchild, and F.R. Johnson Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature Appl Health Econ Health Policy 11 2013 319 329
21. US Food and Drug Administration (FDA). Enhancing benefit-risk assessment in regulatory decision-making. http://www.fda.gov/forindustry/userfees/ prescriptiondruguserfee/ucm326192.htm. Accessed March 1, 2014.
22. A. Mullard Patient-focused drug development programme takes first steps Nat Rev Drug Discov 12 2013 651 652
23. K. Facey, A. Boivin, and J. Gracia et al. Patients' perspectives in health technology assessment: a route to robust evidence and fair deliberation Int J Technol Assess Health Care 26 2010 334 340
24. H.P. Hansen, E. Draborg, and F.B. Kristensen Exploring qualitative research synthesis: the role of patients' perspectives in health policy design and decision making Patient 4 2011 143 152
25. F. Vogt, D. Schwappach, and J. Bridges Accounting for tastes: a German perspective on the inclusion of patient preferences in health care Pharmacoeconomics 24 2006 419 423
26. P. Coplan, R. Noel, and B. Levitan et al. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines Clin Pharmacol Ther 89 2010 312 315
27. US Food and Drug Administration (FDA) Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications. FDA Guidance for Industry and Food and Drug Administration Staff. Silver Spring, Md: Center for Devices and Radiological Health, Center for Biologics Evaluation and Research Food and Drug Administration March 28, 2012
28. R. Fleurence, J.V. Selby, and K. Odom-Walker et al. How the Patient-Centered Outcomes Research Institute is engaging patients and others in shaping its research agenda Health Affairs 32 2013 393 400
29. J. Bridges, A.B. Hauber, and D. Marshall et al. A checklist for conjoint analysis applications in health: report of the ISPOR Conjoint Analysis Good Research Practices Taskforce Value Health 14 2011 403 413
30. Marshall D, Bridges J, Hauber AB, et al. Conjoint analysis applications in health - how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010;3:249-256.
31. J. Bridges, E. Kinter, and A. Schmeding et al. Can patients diagnosed with schizophrenia complete choice-based conjoint analysis tasks Patient 4 2011 267 275
32. J. Coast, T.N. Flynn, and C. Salisbury et al. Maximising responses to discrete choice experiments: a randomised trial Appl Health Econ Health Policy 5 2006 249 260
33. F. Reed Johnson, E. Lancsar, and D. Marshall et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force Value Health 16 2013 3 13
34. International Society for Pharmacoeconomics and Outcomes Research. ISPOR Statistical Methods for Conjoint Analysis Task Force. http://www.ispor.org/ TaskForces/Analyzing-Data-Conjoint-Analysis.asp. Accessed March 1, 2014.
35. S. Erdem, D. Rigby, and A. Wossink Using best-worst scaling to explore perceptions of relative responsibility for ensuring food safety Food Policy 37 2012 661 670
36. T.N. Flynn, J.J. Louvier, T.J. Peters, and J. Coast Best-worst scaling: what it can do for health care research and how to do it J Health Econ 26 2007 171 189
37. J. Bridges Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics Appl Health Econ Health Policy 2 2003 213 224
38. T.N. Flynn Valuing citizen and patient preferences in health: recent developments in three types of best-worst scaling Expert Rev Pharmacoecon Outcomes Res 10 2010 259 267
39. J.J. Louviere, and T.N. Flynn Using best-worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in Australia Patient 3 2010 275 283
40. G. Gallego, J. Bridges, and T. Flynn et al. Using best-worst scaling in horizon scanning for hepatocellular carcinoma technologies Int J Technol Assess Health Care 28 2012 339 346
41. Peay HL, Sheffer H, Tibben A. Expectations and decision making in clinical trials for Duchenne and Becker muscular dystrophy. Abstract presented at: 18th International Congress of The World Muscle Society; October 1-5, 2013; Asilomar, Calif.
42. National Center for Education Statistics. National assessment of adult literacy (NAAL). A first look at the literacy of America's adults in the 21st century. https://nces.ed.gov/pubsearch/pubsinfo.asp?pubid=2006470. Accessed March 1, 2014.
43. D. Townsend, S. Yasuda, and S. Li et al. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle Mol Ther 16 2008 832 835
44. N. Shirokova, and E. Niggli Cardiac phenotype of Duchenne muscular dystrophy: insights from cellular studies J Mol Cell Cardiol 58 2013 217 224
45. Kuhfeld W. Orthogonal arrays [TS-723]. Cary (NC): SAS http://support.sas.com/techsup/technote/ts723.html. Accessed March 1, 2014
46. S.D. Pearson, L. Goldman, and E.J. Orav et al. Triage decisions for emergency department patients with chest pain: do physicians' risk attitudes make the difference? J Gen Intern Med 10 1995 557 564
47. Wallston KA, McNaughton C, Storrow A, et al. Validation of a short, 3-item version of the Subjective Numeracy Scale (SNS-3). Presented at: Health Literacy Research Conference; October 17-18, 2011; Chicago, IL
48. E. Peters, J. Hibbard, P. Slovic, and N. Dieckmann Numeracy skill and the communication, comprehension, and use of risk-benefit information Health Affairs 3 2007 741 748
49. B. Zikmund-Fisher, D.M. Smith, P.A. Ubel, and A. Fagerlin Validation of the Subjective Numeracy Scale: effects of low numeracy on comprehension of risk communications and utility elicitations Med Decis Making 27 2007 663 671
50. A. Fagerlin, B.J. Zikmund-Fisher, and P.A. Ubel et al. Measuring numeracy without a math test: development of the Subjective Numeracy Scale Med Decis Making 27 2007 672 680
51. A. Molassiotis, R. Emsley, and D. Ashcroft et al. Applying best-worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer Lung Cancer 77 2012 199 204
52. D. McFadden Conditional logit analysis of qualitative choice behavior P. Zarembka, Frontiers in Econometrics 1974 Academic Press New York, NY 105 142
53. B.K. Orme Getting Started With Conjoint Analysis: Strategies for Product Design and Pricing Research Research Publishers 2006
54. J. Bridges, A.F. Mohamed, and H.W. Finnern et al. Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis Lung Cancer 77 2012 224 231
55. Peay HL, Hollin I, Sheffer H, Bridges J. Measuring treatment preferences of children with Duchenne muscular dystrophy using best-worst scaling. Presented at the 63rd Annual Meeting of the American Society of Human Genetics; October 23, 2013; Boston, Mass.
56. K. Deal Segmenting patients and physicians using preferences from discrete choice experiments Patient 7 2014 5 21
57. Johnson FR, Hauber AB, Poulos CM. Research Report: A Brief Introduction to the Use of Stated-Choice Methods to Measure Preferences for Treatment Benefits and Risks. RTI Press publication No. RR-0009-0909. Research Triangle Park, NC: RTI International. http://www.rti.org/rtipress. Accessed December 20, 2013